Biphasic 68Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma

被引:65
|
作者
Sahlmann, Carsten-Oliver [1 ]
Meller, Birgit [1 ]
Bouter, Caroline [1 ]
Ritter, Christian Oliver [2 ]
Stroebel, Philipp [4 ]
Lotz, Joachim [2 ]
Trojan, Lutz [3 ]
Meller, Johannes [1 ]
Hijazi, Sameh [3 ]
机构
[1] Univ Med Ctr Goettingen, Dept Nucl Med, Robert Koch Str 40, D-37075 Gottingen, Germany
[2] Univ Med Ctr Goettingen, Dept Diagnost & Intervent Radiol, D-37075 Gottingen, Germany
[3] Univ Med Ctr Goettingen, Dept Urol, D-37075 Gottingen, Germany
[4] Univ Med Ctr Goettingen, Dept Pathol, D-37075 Gottingen, Germany
关键词
Prostate carcinoma; PSMA; HBED; PET; PET/CT; 68Ga; DUAL-TIME-POINT; GA-68-LABELED PSMA LIGAND; BIOCHEMICAL RECURRENCE; PET; DIAGNOSIS; IMPACT;
D O I
10.1007/s00259-015-3251-y
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose Binding of Ga-68-PSMA-HBED-CC (Ga-68-PSMA) at prostate cancer (PC) cells increases over time. A biphasic protocol may help separating benign from tumor lesions. The aim of this study was the retrospective evaluation of a diagnostic incremental value of a dual-time point (biphasic) Ga-68-PSMA-PET/CT in patients with prostate cancer. Methods Retrospective analysis of 35 consecutive patients (49-78 years, median 71) with newly diagnosed PC (12/35) or recurrence of PC (23/35). PET/CT (Gemini TF16, Philips) was acquired 1 h and 3 h p. i. of 140-392 MBq (300 MBq median) Ga-68-PSMA, followed by a diagnostic contrast CT. PET findings were correlated with histology or unequivocal CT findings. Semiquantitative PET data (SUVmax, SUV mean) were acquired and target-to-background-ratios (T/B-ratio) were calculated for benign and malign lesions for both time points. Size of lymph nodes (LN) on diagnostic CT was recorded. Statistical analysis was performed for assessment of significant changes of semiquantitative PET-parameters over time and for correlation of size and uptake of lymph nodes. Results One hundred and four lesions were evaluated. Sixty lesions were referenced by histology or unequivocal CT findings, including eight (13.3 %) histopathologically benign lymph nodes, 12 (20 %) histopathologically lymph node metastases, 12 (20 %) primary tumors, three (5 %) local recurrences, and 25 (41.7 %) bone metastases. Forty-four lesions were axillary LN with normal CT-appearance. Benign lesions had significantly lower SUVmax and T/B-ratios compared with malignant findings. Malign lesions showed a significant increase of both parameters over time compared to benign findings. There was no correlation between LN size and SUVmax. The sensitivity, specificity, the positive predictive value and negative predictive value of PET/CT regarding pelvic LN was 94 %, 99 %, 89 %, and 99.5 %, respectively. Conclusions In contrast to benign tissues, the uptake of proven tumor lesions increases on Ga-68-PSMA-PET/CT over time. A biphasic PET-study may lead to a better detection of tumor lesions in unequivocal findings.
引用
收藏
页码:898 / 905
页数:8
相关论文
共 50 条
  • [41] 68Ga-PSMA HBED-CC PET/MRI in intermediate and high-risk prostate cancer improves the intraprostatic tumor localization compared to multiparametric MR
    Eiber, Matthias
    Weirich, Gregor
    Holzapfel, Konstantin
    Souvatzoglou, Michael
    Haller, Bernhard
    Wester, Hans-J A.
    Maurer, Tobias
    Schwaiger, Markus
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [42] Clinical accuracy of detecting recurrent prostate cancer lesions with F-18-Fluoroethylcholine or Ga-68-PSMA-HBED-CC PET/CT.
    Pfister, David J. K. P.
    Porres, Daniel
    Heidenreich, Axel
    Behrendt, Florian
    Verburg, Frederik
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [43] Re: Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-ligand-PET/CT Before Salvage Lymph Node Dissection for Recurrent Prostate Cancer
    Hadaschik, Boris
    Herrmann, Ken
    EUROPEAN UROLOGY, 2017, 72 (03) : 470 - 471
  • [44] Biodistribution and radiation dosimetry of 68Ga-PSMA HBED CC—a PSMA specific probe for PET imaging of prostate cancer
    Christian H. Pfob
    Sibylle Ziegler
    Frank Philipp Graner
    Markus Köhner
    Sylvia Schachoff
    Birgit Blechert
    Hans-Jürgen Wester
    Klemens Scheidhauer
    Markus Schwaiger
    Tobias Maurer
    Matthias Eiber
    European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43 : 1962 - 1970
  • [45] [68Ga]PSMA-HBED-CC PET/CT to differentiate between diffuse bone metastases of prostate cancer and osteopoikilosis
    Behrendt, Florian
    Krohn, Thomas
    Mottaghy, Felix
    Verburg, Frederik A.
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2016, 55 (06): : N64 - N65
  • [46] Antihormonal-Treatment Status Affects 68Ga-PSMA-HBED-CC PET Biodistribution in Patients with Prostate Cancer
    Kluge, Kilian
    Haberl, David
    Einspieler, Holger
    Rasul, Sazan
    Gutschmayer, Sebastian
    Kenner, Lukas
    Kramer, Gero
    Grubmuller, Bernhard
    Shariat, Shahrokh
    Haug, Alexander
    Hacker, Marcus
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (11) : 1730 - 1736
  • [47] The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of prostate cancer
    Akdemir, E.
    Tuncel, M.
    Tuncali, M. C.
    Bilen, C. Y.
    Akyol, F.
    Baydar, D.
    Ozen, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S679 - S679
  • [48] Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging
    Kabasakal, Levent
    Demirci, Emre
    Ocak, Meltem
    Akyel, Resit
    Nematyazar, Jamal
    Aygun, Aslan
    Halac, Metin
    Talat, Zubeyir
    Araman, Ahmet
    NUCLEAR MEDICINE COMMUNICATIONS, 2015, 36 (06) : 582 - 587
  • [49] Imaging of PSMA expression in metastatic differentiated thyroid cancer using 68Ga-HBED-CC-PSMA PET/CT
    Lutje, Susanne
    Benedikt, Gomez
    Cohnen, Joseph
    Umutlu, Lale
    Gotthardt, Martin
    Poeppel, Thorsten
    Bockisch, Andreas
    Rosenbaum-Krumme, Sandra
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [50] Follicular Lymphoma Showing Avid Uptake on 68Ga PSMA-HBED-CC PET/CT
    Kanthan, Gowri L.
    Coyle, Luke
    Kneebone, Andrew
    Schembri, Geoffrey Paul
    Hsiao, Edward
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (06) : 500 - 501